Kingsview Wealth Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q3
Sell
-422
Closed -$1K 442
2018
Q2
$1K Sell
422
-632
-60% -$21.6K ﹤0.01% 374
2018
Q1
$3K Buy
+1,054
New +$36.2K ﹤0.01% 334
2017
Q4
Sell
-527
Closed -$1K 427
2017
Q3
$1K Sell
527
-632
-55% -$20.3K ﹤0.01% 352
2017
Q2
$3K Hold
1,159
﹤0.01% 305
2017
Q1
$3K Buy
+1,159
New +$36.5K ﹤0.01% 269

Other funds holding PFE

Kingsview Wealth Management's PFE Position: Q1 2026 in Review

Kingsview Wealth Management increased its Pfizer (PFE) stake by 2.2% in Q1 2026, buying an estimated $129K and bringing the position to 221,263 shares worth $6.21M. The position accounts for 0.08% of the portfolio, ranked #256.

Kingsview Wealth Management first reported a position in PFE in Q1 2017 and has held it in 37 quarters since. The position peaked at $8.27M in Q2 2024. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Kingsview Wealth Management held 221,263 shares of Pfizer worth $6.21M as of Q1 2026.
  • Kingsview Wealth Management bought 4,848 Pfizer shares in Q1 2026, an estimated $129K.
  • Pfizer made up 0.08% of Kingsview Wealth Management's portfolio in Q1 2026, its #256 holding.
  • Kingsview Wealth Management first reported a position in Pfizer in Q1 2017 and has held it in 37 quarters since.
  • Kingsview Wealth Management's Pfizer position peaked at $8.27M in Q2 2024.
  • 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Kingsview Wealth Management's 13F filing for Q1 2026, filed 12 May 2026.